Publications by authors named "A Faucon"
Introduction: Little is known regarding the comparison of cardiovascular and kidney outcomes between lupus nephritis (LN) and other etiologies of chronic kidney disease (CKD).
Methods: Using data from the Swedish Renal Registry (2006-2021), we compared long-term outcomes between patients with LN-CKD and patients with CKD due to primary glomerular diseases (PGD) and other CKD causes (Other-CKD, mainly diabetes and nephroangiosclerosis). Adjusted hazard ratios (HRs) of mortality, major adverse cardiovascular events (MACE) and kidney replacement therapy (KRT) were estimated using Cox proportional hazard models.
Importance: COVID-19 infection has been associated with acute kidney injury. However, its possible association with long-term kidney function is not well understood.
Objective: To investigate whether kidney function decline accelerated after COVID-19 compared with after other respiratory tract infections.
Objective: Low estimated glomerular filtration rate (eGFR) increases the risk of arterial diseases, possibly including abdominal aortic aneurysm (AAA). This study explored the relationship between eGFR (2008 CKD-EPI equation), annual eGFR decline, and subsequent risk of developing AAA in a large, community based sample.
Methods: This was an observational study using complete healthcare records of Stockholm residents free from AAA who underwent routine creatinine testing during 2011 - 2021.
Article Synopsis
- Glomerular diseases rank as the third most common cause of end-stage kidney disease worldwide, yet their long-term outcomes remain poorly understood.
- In a study involving almost 2,400 patients with primary glomerular diseases, researchers found that these patients typically had lower hospitalization and mortality rates compared to those with chronic kidney disease from common non-communicable diseases.
- Notably, patients with IgA nephropathy (IgAN) and focal segmental glomerulosclerosis (FSGS) experienced faster declines in kidney function and higher rates of kidney replacement therapy compared to those with minimal change disease (MCD) and membranous nephropathy (MN), indicating a need for more aggressive treatment approaches for IgAN and F
Article Synopsis
- A study was conducted to determine if sodium-glucose cotransporter-2 inhibitors (SGLT-2i) reduce the risk of hyperkalemia and help maintain the use of renin-angiotensin system inhibitors (RASi) in people with type 2 diabetes, compared to dipeptidyl peptidase 4 inhibitors (DPP-4i).
- The research involved nearly 30,000 adults in Stockholm over several years, measuring incidents of hyperkalemia and RASi discontinuation in those starting either SGLT-2i or DPP-4i.
- Results showed that SGLT-2i users had significantly lower rates of hyperkalemia (both mild and